Altamira Therapeutics Accounts Payable

Altamira Therapeutics (CYTO) currently reports a accounts payable of $520K as of December 2024. That compares with $410K in the prior-year period — up 27.0% year over year. Use the charts on this page to explore Altamira Therapeutics's accounts payable history and peer comparisons.

Altamira Therapeutics's accounts payable increased from $410K to $520K — a 27.0% year-over-year increase (period ending December 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Altamira Therapeutics reported $520K in accounts payable as of December 2024. That compares with $410K in the prior-year period — up 27.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $520K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Altamira Therapeutics, and consider following CYTO for alerts when major investors trade the stock.

Altamira Therapeutics is classified in the Healthcare sector. On accounts payable, it currently shows $520K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CYTO with unrelated industries.